Although it is arguable as to whether plants have all five human senses -- sight, scent, hearing, taste and touch -- they do have a unique sense of gravity, which is being tested in space.
As NASA develops deep space exploration missions on its journey to Mars, the agency is investigating current training methods in order to adapt to the longer and longer missions.
Defending websites from malicious intruder bots is not unlike fighting viruses: neutralize them and they reinvent themselves, finding new ways to penetrate. But IT security designers still hold an advantage over some automated programs masquerading as people. To date, there are human abilities too complex to imitate.
After two years of upgrades and repairs, proton beams once again circulate around the Large Hadron Collider at CERN. Oak Ridge National Laboratory has led an eight-year upgrade of the electromagnetic calorimeter used for LHC's experiment called ALICE (for A Large Ion Collider Experiment). This detector measures the energies of high-energy electrons and gamma rays to learn more about the conditions of the early universe.
Office of Naval Research officials announced today new research support to develop a prototype diving helmet that could revolutionize diving missions -- and provide greater safety for divers.
The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc. have signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia.
Palos Community Hospital and Loyola University Medical Center have announced plans to join together to create an innovative affiliation in Illinois. With a focus on coordinated and collaborative patient care, the affiliation presents a new way to build a network of care that doesn't involve mergers, acquisitions or consolidations, a trend in today's evolving health care landscape.
A suite of analytical innovations used to detect and measure very low levels of compounds and elements has topped $10 million in licensing income for Pacific Northwest National Laboratory and its operator Battelle. It's the first time that income tied to a specific technology developed at PNNL has reached this level.
Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease. The small molecule is based on longstanding, groundbreaking biology work by a Sanford-Burnham scientist and his laboratory team, who for decades focused their research on treating a consequence of cardiovascular-metabolic disease.
A clinical trial using personalized cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease, a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient.